research use only
Cat.No.S8238
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor ATPase GluR |
|---|---|
| Other TRP Channel Inhibitors | SKF96365 2-APB (2-Aminoethyl Diphenylborinate) AMG-517 GSK2193874 GSK1016790A HC-030031 Capsazepine EIPA (L593754) HC-067047 SB705498 |
|
In vitro |
DMSO
: 57 mg/mL
(198.09 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 287.74 | Formula | C16H14ClNO2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 472981-92-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=CC=CC(=C1)NC(=O)C=CC2=CC=C(C=C2)Cl | ||
| Targets/IC50/Ki |
TRPV1
(Cell-based assay) 5.7 nM
|
|---|---|
| In vitro |
SB-366791 is a structurally novel and potent TRPV1 antagonist which is capable of inhibiting the capsaicin-, acid- and heat-mediated activation of the receptor but produces little or no effect on a wide range of enzymes, ion channels, GPCRs and other proteins. This compound may prove to be a better tool for unambiguously defining the (patho)physiological role of TRPV1.
|
| In vivo |
the TRPV1 antagonist SB366791 reduces the number of flinches but did not improve ambulation and weight-bearing. A sub-analgesic dose of this compound potentiates the effects of morphine at doses of
3.0 and 10.0 mg/kg on flinches and weight-bearing but not ambulation. The combination of morphine and this chemical has potent analgesic effects on bone cancer pain.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.